MDR classification logic
Brazil's 22 classification rules were adopted from EU MDR Annex VIII. Your classification rationale and much of your technical reasoning transfer as a starting point.
Saves: analysis time, not the filingLatin America's largest healthcare market runs on one regulator, one mandatory local holder and a strict order of operations. The good news for German manufacturers: Brazil's device classification was rebuilt on the EU MDR rules, so much of what you already have travels. The catch is who holds your registration — and it cannot be you.
Brazil regulates medical devices under RDC 751/2022 (in force since March 2023): four risk classes, and 22 classification rules adopted from EU MDR Annex VIII — so a German manufacturer's MDR classification largely carries over. Class I and II go through Notification; Class III and IV need full Marketing Authorization, valid ten years, plus a Brazilian GMP certificate. A foreign manufacturer cannot hold the registration: you must appoint a Brazilian Registration Holder (BRH) with a valid operating licence. Some devices need INMETRO certification before ANVISA. And approval only makes you eligible for the SUS public system — it does not sell anything.
Brazil is the most structured of the big emerging markets. That is an advantage — the rules are knowable — provided you respect the order they come in.
For German medtech there is a genuine head start: when ANVISA rewrote its device framework in RDC 751/2022, it expanded classification from 18 to 22 rules and adopted them from Annex VIII of the EU MDR. If your product is classified under MDR, you are not starting from a blank page in Brazil.
What has no European equivalent is the holder rule. In Germany you can be the manufacturer and, through an entity or an authorised representative, control your own registration. In Brazil the registration is held by a Brazilian legal entity, its details appear on your label, and the requirement is not waivable.
Brazil will recognise your engineering. It will not let you hold your own registration.
Brazil is unusual in how strictly the steps must be taken in sequence. Certification comes before registration, not alongside it — and the holder must exist before anything can be filed.
Four risk classes (I–IV) using 22 rules adopted from EU MDR Annex VIII. Your existing MDR classification is the starting point, not a guess.
A Brazilian legal entity with a valid operating licence (Autorizacao de Funcionamento, AFE). Nothing can be filed without it. Not waivable.
Required before ANVISA for most electro-medical devices (IEC 60601) and certain others such as hypodermic needles, surgical gloves, breast implants and condoms.Before, not during
The manufacturing site needs a valid Brazilian GMP certificate issued by ANVISA, following inspection. An MDSAP audit report can be accepted in place of a separate ANVISA inspection.MDSAP saves months
Notification for Class I and II; Marketing Authorization for Class III and IV, valid ten years and renewable for equal successive periods. Plan roughly four to eight months for the process.
Registration makes you eligible for SUS public procurement and the private market. It does not win either.
Which route you take, and how heavy it is, follows directly from the risk class.
| Risk class | Pathway | Also required |
|---|---|---|
| Class I — low | Notification (cadastro) | BRH; INMETRO if the product type demands it. |
| Class II — medium | Notification | BRH; INMETRO where applicable. |
| Class III — high | Marketing Authorization (registro), valid 10 years | BRH; Brazilian GMP certificate for the manufacturing site; INMETRO where applicable. |
| Class IV — maximum | Marketing Authorization, valid 10 years | BRH; Brazilian GMP certificate; INMETRO where applicable. |
The jump from Class II to Class III is where the cost and calendar change shape — a site inspection enters the picture. Confirming your class early is the cheapest decision in the whole project. Compare with how classification drives cost in Germany in MDR vs IVDR.
This is the single most consequential choice in a Brazilian entry — and the one most often made carelessly, by defaulting to whoever offered to distribute.
The BRH is a Brazilian legal entity holding a valid operating licence from ANVISA. It acts as the applicant before approval and carries responsibility for the device afterwards. It is not an administrative convenience: the BRH maintains the technical documentation behind the registration, handles complaints and adverse-event reporting to ANVISA, coordinates any field safety corrective action, and is the regulator's primary channel for your product throughout its commercial life. Its details appear on the labelling.
A registration held by your distributor means the legal permission to sell your device in Brazil sits with a company whose interests may diverge from yours. Changing partners then means renegotiating from a weak position — or re-registering, with the time and cost that implies.
The alternative is deliberate: appoint an independent BRH (a regulatory service provider) or your own Brazilian entity as holder, and contract distribution separately. It costs more up front and it keeps the market yours. This is the same structural question we flag on every corridor — see Southeast Asia, where the identical trap appears under different names.
Two genuine accelerators exist for a German manufacturer. Both are worth planning around.
Brazil's 22 classification rules were adopted from EU MDR Annex VIII. Your classification rationale and much of your technical reasoning transfer as a starting point.
Saves: analysis time, not the filingBrazil participates in the Medical Device Single Audit Program. An MDSAP report can be accepted instead of a separate ANVISA inspection for the GMP certificate.
Saves: potentially months on Class III/IVWhat does not travel: the CE mark itself confers nothing in Brazil; documentation must be in Portuguese; and INMETRO certification is a separate national conformity step with its own accredited bodies and timeline. Budget for translation and for the sequencing, not just the fees. The wider cost logic is the same one we set out for inbound medtech in the real cost of entering a market.
Brazil's public health system, the SUS, serves the majority of the population. ANVISA registration is what makes you eligible to be procured by it — nothing more.
Registered means allowed. Procured means chosen. In Brazil those are separated by an entire commercial project.
Start with a fixed, written deliverable for the Brazilian corridor, then plan execution in a working session — especially the holder decision, which is expensive to reverse.
A one-off written roadmap for Brazil — the classification, the sequence and the holder question, before you sign anything.
A focused session to structure the holder relationship, weigh SUS against the private market, and plan the first year.